Cargando…
Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization....
Autores principales: | Patrawala, Meera, Kuruvilla, Merin, Li, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063228/ https://www.ncbi.nlm.nih.gov/pubmed/32181140 http://dx.doi.org/10.1016/j.ymgmr.2020.100575 |
Ejemplares similares
-
Case-control study about the acceptance of Pegvaliase in Phenylketonuria
por: Krämer, Johannes
Publicado: (2020) -
Evidence- and consensus-based recommendations for the use of
pegvaliase in adults with phenylketonuria
por: Longo, Nicola, et al.
Publicado: (2018) -
A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria
por: Hydery, Tasmina, et al.
Publicado: (2019) -
Nutritional status of adults with phenylketonuria on pegvaliase: A 15-month prospective study
por: Viau, Krista, et al.
Publicado: (2023) -
A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences
por: Sri Bhashyam, Sumitra, et al.
Publicado: (2019)